NCT05583188 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05583188
Title	Neoadjuvant Aliya PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC (VIGOR)
Acronym	VIGOR
Recruitment	Terminated
Gender	both
Phase	FDA approved
Variant Requirements	No
Sponsors	Galvanize Therapeutics, Inc.
Indications	lung non-small cell carcinoma
Therapies	Cisplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Nivolumab Carboplatin Cisplatin + Nivolumab + Paclitaxel Carboplatin + Docetaxel + Nivolumab Cisplatin Carboplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Paclitaxel Pemetrexed Disodium Vinorelbine Gemcitabine Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium
Age Groups:	adult \| senior
Covered Countries	USA

Facility	City	State	Zip	Country	Details
Mayo Clinic Rochester	Rochester	Minnesota	55905	United States	Details
University of Pennsylvania	Philadelphia	Pennsylvania	19104	United States	Details
Temple University	Philadelphia	Pennsylvania	19122	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT05583188Clinical Trial Detail